GenEdit and Editas announce a worldwide, exclusive license and collaboration to enable safer and more effective delivery of CRISPR-based therapeutics.
Lummus Strengthens Position in Circular Economy - Investment in Resynergi will scale groundbreaking microwave pyrolysis...
